Oncology is the single largest market in the global biopharma industry, worth over $200B. Here's a look at the top 15 drugs in the space, and some insights behind the numbers:

1. Several top sellers are facing LOEs soon: Pfizer's Ibrance faces competition in 2027, while Merck's Keytruda and BMS's Opdivo face expirations in 2028.

2. 4 drugs gained over $1B each in addition sales compared to 2022:
Keytruda (up $4.1B) Darzalex (up $1.8B) Imfinzi (up $1.5B) and Verzenio (up $1.4B).

The biggest decliner was BMS's Revlimid, which saw sales drop by almost $4B from 2022.

3. It is notable just how much these drugs depend on the US market for revenue - for several of the top drugs (e.g., Darzalex, Opdivo, and Ibrance), US sales accounted for well over 50% of total revenue.

The next few years have a lot in store - major LOEs, new modalities like ADCs, and more favorable capital markets - all of which will continue to make oncology one of the most dynamic parts of biopharma.